SHEN26

SHEN26
Identifiers
	IUPAC name [(2R,4S,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methyl cyclohexanecarboxylate;
PubChem CID	170836238;
Chemical and physical data
Formula	C19H23N5O5
Molar mass	401.423 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCC(CC1)C(=O)OC[C@@H]2C([C@@H]([C@](O2)(C#N)C3=CC=C4N3N=CN=C4N)O)O;
	InChI InChI=InChI=1S/C19H23N5O5/c20-9-19(14-7-6-12-17(21)22-10-23-24(12)14)16(26)15(25)13(29-19)8-28-18(27)11-4-2-1-3-5-11/h6-7,10-11,13,15-16,25-26H,1-5,8H2,(H2,21,22,23)/t13-,15?,16+,19+/m1/s1; Key:NJZZWWHRMAGFGB-TVMOFBLASA-N;

SHEN26 is an investigational new drug which is being evaluated by Shenzhen Kexing Pharmaceuticals for the treatment of COVID-2019. It is an RNA replicase inhibitor.^[1]^[2]

References

^ "SHEN 26". AdisInsight. Springer Nature Switzerland AG.
^ Sun C, Liu H, Ouyang Z, Ding J, Zhang Q, Ma H, et al. (May 2024). "Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects". Expert Opinion on Investigational Drugs. 33 (5): 533–542. doi:10.1080/13543784.2024.2347302. PMID 38662639.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.